Healthcare
InfuSystem Holdings, Inc.(INFU)
Live Price
Offline$9.01
-2.49% today
1Y Change
+36.72%
Window
Jun 25, 2025 โ Jun 17, 2026
- Market Cap
- $200.00M
- Revenue Growth
- +6.4%
- EPS Growth
- +190.9%
- Dividend Yield
- 0.0%
Coverage: 246 bars ยท Jun 25, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
InfuSystem Holdings, Inc. (INFU) is a Healthcare stock with a market cap of $200.00M and listed on AMEX. The stock last traded around $9.01 and up 36.7% across the available one-year price window (Jun 25, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +6.4%, EPS growth of +190.9%, a dividend yield of 0.0%. What stands out right now is revenue +6.4%, EPS +190.9%, free cash flow +808.1% with operating margin 8.3% and ROIC 13.3%. Valuation already assumes a fairly strong business story at P/E 31.0 and price/sales 1.4. Stock Foundry combines INFU price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.4% vs +7.6% peer median
Operating Margin
Below sector median
+8.3% vs +19.4% peer median
P/E
Below sector median
31.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +6.4% and EPS at +190.9%, with operating margin around 8.3%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +10.9% over the next 5 trading days and finished higher after 3 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | +1.9% | +15.4% | +6.2% |
2026 Feb 24, 2026 | +42.9% | -0.5% | +6.7% | +12.7% |
2025 Nov 4, 2025 | +37.5% | +5.7% | +10.5% | -1.3% |
Benchmark Edge
INFU vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
INFU
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
INFU Max Drawdown
-31.17%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for INFU and SPY.
Company Overview
InfuSystem Holdings, Inc.
New York Stock Exchange American
InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other alternate site settings comprising home care and home infusion providers, skilled nursing facilities, pain centers, hospital market, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.
- Leadership
- Carrie A. Lachance
- IPO Date
- Dec 27, 2007
- Employees
- 502
- Street Address
- 3851 West Hamlin Road
- Mailing
- Rochester Hills, MI, 48309
- Region
- Rochester Hills, MI, US
- Reporting Currency
- USD
- Investor Line
- 248 291 1210
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 31.0
- EV/EBITDA
- 8.1
- Price/Sales
- 1.4
- Price/Book
- 3.6
Growth
- Revenue
- +6.4%
- EPS
- +190.9%
- Free Cash Flow
- +808.1%
Profitability
- Gross Margin
- 56.0%
- Operating Margin
- 8.3%
- Net Margin
- 4.6%
- ROE
- 11.9%
- ROIC
- 13.3%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 1.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.